Benzinga

Benzinga

Benzinga

martedì, settembre 01

Lifecore Biomedical Inc

LFCRNASDAQ
Trade with Public
Trade with Public
$4.46
-0.08-1.76%
In chiusura: Aug 28, 5:00 PM EST
$4.46
-0.08-1.76%
Pre-mercato: 4:00 AM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Lifecore Biomedical Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lifecore Biomedical (LFCR).

Price Target Range — 6 Quarters

Analyst Consensus — 3 Analysts

3Buy
Consensus RatingBuy# Analysts3Avg. Consensus PT$8Upside to Avg. PT+68.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 16, 2026Barrington ResearchMichael PetuskyPT RaiseOutperform$6→$7
Apr 29, 2026Barrington ResearchMichael PetuskyPT RaiseOutperform$6→$6
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6.5

Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $6 to $6.5.
Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6

Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $5.5 to $6.
Benzinga Newsdesk

PRO
Barrington Research Upgrades Lifecore Biomedical to Outperform, Announces $5.5 Price Target

Barrington Research analyst Michael Petusky upgrades Lifecore Biomedical (NASDAQ:LFCR) from Market Perform to Outperform and announces $5.5 price target.
Benzinga Newsdesk

Lifecore Stock Sinks As Delayed Launches Push Growth Further Out

Lifecore stock plunges after earnings miss and weak 2026 outlook, with customer losses and delayed growth plans weighing on shares.
Vandana Singh

PRO
Keybanc Initiates Coverage On Lifecore Biomedical with Sector Weight Rating

Keybanc analyst Paul Knight initiates coverage on Lifecore Biomedical (NASDAQ:LFCR) with a Sector Weight rating.
Benzinga Newsdesk

PRO
William Blair Initiates Coverage On Lifecore Biomedical with Outperform Rating

William Blair analyst Max Smock initiates coverage on Lifecore Biomedical (NASDAQ:LFCR) with a Outperform rating.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved